الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
• Breast cancer is the most common cancer in women worldwide. It is estimated that more than 1.7 million new cases of breast cancer occurred among women worldwide in 2012 (most recent data available).
• About 1 of 5 breast cancers have too much of a growth-promoting protein calledHER2/neu (often just shortened to HER2). The HER2/neugene instructs the cells to make this protein.
• Patients with HER-2–positive disease demonstrate adverse disease characteristics presentation (larger tumor size, higher tumor grade, and lymph node invasion), have shorter survival times, and have a higher risk for disease recurrence or progression. These features highlight the attractiveness of HER-2 as a potential treatment target.
• Trastuzumab is the first of such agents which was registered for use in patients with HER2-overexpressing breast cancer. Trastuzumab is a humanised mAb of the immunoglobulin G1 type directed against the extracellular portion of HER2.
• In this retrospective study , we presented data on 50 female patients , diagnosed as her2 positive breast cancer, 25 of them ( 50% ) were diagnosed as early stages , the others were diagnosed as advanced stages . About 20 patients ( 40%) were ER,PR +ve & (60%) were ER,PR –ve, with median follow up 26,66 months. all the 50 recruited patients had received adjuvant chemotherapy & adjuvant 1 year of trastuzumab , without delaying in intiation ≤ 6 months after diagnosis , and that had had a dramatic effects ,12% of patients (n=6) received neoadjuvant chemotherapy , 78% of patients (n=39) received adjuvant radiotherapy (were node positive), all the recrutied patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant metastases (p value= 0.001) with a significant impact on DFS & OS.
• Trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients, according to several studies which alsohelp to highlight the efficacy of TRASTUZUMAB in the treatment of her2 over expression breast cancer patients.